Clinical Safety

Can Korean Biotech Redefine Next-Gen Cancer Treatments?
Research & Development Can Korean Biotech Redefine Next-Gen Cancer Treatments?

The 2026 American Association for Cancer Research annual meeting in San Diego stands as a definitive proving ground where South Korean biotechnology firms must transition from theoretical promise to clinical validation. Unlike later-stage conferences such as ASCO or ESMO, the AACR provides a unique

UC Riverside Researchers Create Low-Cost Tool to Detect Fake Pills
Research & Development UC Riverside Researchers Create Low-Cost Tool to Detect Fake Pills

The global marketplace for pharmaceuticals has reached a critical inflection point where the sheer volume of counterfeit medications now threatens the fundamental integrity of international healthcare systems and patient safety alike. As criminal networks become more sophisticated in replicating

Henlius Challenges Pfizer in PD-L1 Lung Cancer Drug Race
Research & Development Henlius Challenges Pfizer in PD-L1 Lung Cancer Drug Race

The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,

Mirum Completes Enrollment for Phase 3 Maralixibat Trial
Research & Development Mirum Completes Enrollment for Phase 3 Maralixibat Trial

The relentless physical and psychological burden of chronic cholestatic pruritus often defines the daily existence of patients long before a clinical diagnosis is even finalized. For those living with rare liver diseases, the sensation of an internal, unreachable itch is not merely a symptom but a

Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%
Research & Development Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%

The current oncology landscape is defined by an urgent need for therapies that can bypass resistance mechanisms in advanced breast cancer while maintaining patient quality of life. Pfizer’s latest clinical data for atirmociclib suggests a significant advancement in achieving this balance through a

Neflamapimod Shows Promise in Slowing ALS Progression
Research & Development Neflamapimod Shows Promise in Slowing ALS Progression

The battle against Amyotrophic Lateral Sclerosis (ALS) has long been defined by a relentless search for therapeutic interventions capable of altering the grim prognosis associated with this rapid neurodegenerative decline. As a condition that systematically dismantles the motor neuron network, ALS

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later